2月10日上午，聊城华厦眼科（301267）医院首例EVO+ICL(V5)新型晶体植入手术成功开展，这是全国首批此类手术，标志着聊城华厦眼科医院在屈光矫 正领域实现了技术再升级，也为更多近视患者带来了更精准、舒适的摘镜新选择。 据了解，本次手术的患者是一名在校大学生，21岁。该患者的眼部屈光情况较为复杂，双眼近视度数均近1000度，并伴有200余度散光(右眼：875度近视 +250度散光；左眼：975度近视+225度散光)。 未来，医院也将持续深耕屈光领域，依托专家团队与全流程质量管理体系，为不同视力困扰的人群，尤其是高度近视群体，提供更先进、高质且个性化的 视觉健康解决方案，助力更多人实现清晰视界的梦想。 本次手术由聊城华厦眼科医院屈光手术专家于瑞云亲自主刀。术前，聊城华厦眼科屈光团队为患者进行了全面细致的眼部检查，结合其职业特点和眼部条 件，量身定制了EVO+ICL(V5)晶体植入手术方案，并详细讲解了手术流程、术式优势及术后注意事项，充分缓解患者紧张情绪。 作为拥有10余年屈光诊疗经验，瑞士STAAR EVO-ICL认证医师的专家，于瑞云院长以精湛娴熟的技术，十分钟左右便完成了V5晶体的精准植入，术中患 ...

近日，医院已成功开展了无锡地区首台EVO+ICL（V5）晶体植入手术。该手术由无锡华厦眼科医院近 视手术专家顾勇院长主刀完成，标志着无锡近视矫正迈入更精准、更个性化的新阶段，将为众多受夜间 视力困扰的近视患者带来新的解决方案。 2026年1月，被业界誉为"夜间视觉优化版"的EVO+ICL（V5）——新一代可植入式接触镜正式进入无 锡。无锡华厦眼科（301267）医院成为无锡率先引进这一技术的医疗机构。 患者故事，从夜间困扰到清晰视界 林女士是无锡华厦眼科首位接受EVO+ICL（V5）晶体植入的近视患者。作为高度近视者，她的生活深 受厚重镜片影响，而夜跑这一放松方式也因夜间视力问题变得困难。 然而，高度近视已成了她享受夜间活力的最大阻碍。框架眼镜在运动中太不方便，但更困扰她的是夜间 视力——路灯的光晕、球场灯光的眩光，让她的视界一片模糊，不仅影响发挥，也存在安全隐患。对夜 间视觉品质的高要求，让她对常规近视矫正手术心存疑虑。 了解到无锡华厦眼科医院引进的EVO+ICL（V5）晶体专门针对夜间视觉优化时，林女士看到了希望。 经检查，她的较大暗瞳条件恰好与EVO+ICL（V5）晶体扩大光学区的设计优势相匹配。 手术 ...

证券日报网讯2月4日，华厦眼科（301267）在互动平台回答投资者提问时表示，公司始终关注眼科诊疗 新设备、新技术的发展，积极引进国内外先进的眼科诊疗技术和设备。在国产设备方面，公司与国内主 要的设备厂商均建立了长期稳定的联系，未来公司将根据临床应用需求及技术成熟度，逐步推进国产设 备的引进和应用，为患者提供优质、多元化的诊疗服务。 ...

日前，"见未来·2025第八届金禧奖年度评选"结果揭晓，华厦眼科医院集团凭借系统性、引领性、实效 性的品牌创新实践，从众多参选企业中脱颖而出，荣膺"金禧奖·2025创新品牌奖"。 "金禧奖"是由标点财经研究院联合《投资时报》、投资时间网等第三方机构，基于对数千家企业的大数 据分析、比较，再经媒体记者、研究员团队专业评审而产生，以其客观、公正、权威的研究属性，深受 市场认可。 荣获"2025品牌创新奖"，是华厦眼科继入选"中国上市公司品牌价值榜"新锐榜TOP50，获评"国民信赖 十大健康品牌""卓越品牌管理公司""优秀品牌案例"之后，再度斩获的又一重要品牌类殊荣。 "此次获奖，是华厦眼科在品牌建设上持续深耕、从量变到质变的一个标志，助力品牌从'被知晓'到'被 信赖'的价值建设"。华厦眼科医院集团品牌负责人施晶总结道，这一跨越的根本是集团始终恪守"一切 以病人为中心"的理念，致力于让专业的医疗价值、温暖的社会价值与开放的生态价值协同共振，让品 牌成为一份可感知、可分享、可持续的光明承诺。 以创新聚势，筑百年华厦 品牌创新是企业破局生长的"必修课"，亦是抵御市场不确定性的"压舱石"与连接用户的"强纽带"。 作为大型 ...

经营范围含许可项目：医疗服务；第三类医疗器械经营；药品零售。（依法须经批准的项目，经相关部 门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准）诊所服务；第一类医 疗器械销售；第二类医疗设备租赁；眼镜销售（不含隐形眼镜）；个人卫生用品销售；日用百货销售； 日用品销售；食品销售（仅销售预包装食品，不含酒）；保健食品（预包装）销售；照明器具制造；电 子产品销售；卫生用品和一次性使用医疗用品销售；家居用品销售；医护人员防护用品零售。（除依法 须经批准的项目外，凭营业执照依法自主开展经营活动）。 天眼查显示，近日，厦门同安华厦眼科诊所有限公司成立，法定代表人为陈向东，注册资本500万人民 币，由厦门华厦视光中心有限公司全资持股。 序号股东名称持股比例1厦门华厦视光中心有限公司100% 企业名称厦门同安华厦眼科诊所有限公司法定代表人陈向东注册资本500万人民币国标行业卫生和社会 工作>卫生>医院地址厦门市同安区南门路102号、104号企业类型有限责任公司（自然人投资或控股的 法人独资）营业期限2026-1-22至无固定期限 来源：市场资讯 ...

近日，2025第六届TBI杰出品牌创新奖获奖结果在上海正式揭晓。华厦眼科凭借集专业实力、创新能力 与发展潜力于一体的品牌综合优势，成功斩获"年度品牌奖"。 华厦眼科品牌部负责人施晶(右数第6位)登台领奖 "提供品质专业的医疗服务，是华厦品牌最亮丽的主色调。"施晶强调。 华厦眼科坚持"医教研"一体化发展，是国内少数拥有"双三甲"的大型眼科医疗连锁集团，也是全国唯一 同时拥有3位国际眼科科学院院士的眼科机构。同时，集团建立了眼科全科诊疗服务体系，不断加大在 引进国际先进设备、科研创新及人才培养方面的投入，持续提升医疗质量与服务体验，为患者提供优质 的诊疗服务。 释放社会价值，以公益传递品牌温度。 TBI杰出品牌创新奖(Top Brand Innovation Awards)已经走过6年，是中国极具影响力的综合性权威荣誉。 奖项深度关注数字时代的品牌增长路径，聚焦以创新理念赋能创建、维护与价值增长的完整链路，旨在 发掘并致敬兼具创新魄力、前瞻视野与实用价值的品牌典范。 本届奖项在为期3个月的征集中，吸引了包括雀巢、一汽大众、蒙牛、安踏、可口可乐、vivo、云南白 药、方太、名创优品、FILA、双汇、周大生、国药大健 ...

Core Viewpoint - The "domestically produced all-laser refractive surgery machine" developed by Professor Zhang Mingchang's team has been recognized as one of the "Top Ten Original Advances in Ophthalmology in China for 2025," marking a significant breakthrough in the field of high-end laser treatment equipment for myopia refractive surgery in China [1][7]. Group 1: Research and Development Achievements - Professor Zhang Mingchang's team has been dedicated to the innovation and research of ocular surface diseases and refractive treatment technologies [3][9]. - The team previously developed the "tear lipid content detection test strip," which was included in the "Top Ten Advances in Chinese Ophthalmology" in 2021 [3][9]. Group 2: Technological Breakthroughs - The newly developed device achieves significant technological breakthroughs in laser energy control, beam positioning accuracy, and surgical process stability, specifically designed for myopia refractive surgery [5][11]. - The core optical system and intelligent control platform of the device are entirely developed domestically, breaking the long-standing reliance on imported equipment [5][11]. Group 3: Market Impact and Future Prospects - The device is expected to provide higher quality and more accessible high-end refractive surgery options for myopia patients, potentially lowering surgical costs and benefiting many individuals seeking vision correction [5][11]. - The development and transformation of this achievement exemplify successful collaboration between medical engineering and industry-academia partnerships, promoting the localization of high-end ophthalmic treatment equipment and supporting the self-control and technological upgrades of the related industry chain [12]. - Looking ahead, the team plans to deepen collaboration with the industry to promote more original and leading technologies for clinical application, contributing to the high-quality development of eye health in China and supporting the "Healthy China" strategic goal [14].

Core Insights - The biopharmaceutical industry in China is a strategic emerging industry, crucial for public health, technological innovation, and enhancing national pharmaceutical autonomy. The market size is projected to grow from CNY 4,210 billion in 2022 to CNY 8,000 billion by 2028, with an annual growth rate stabilizing between 10%-12% [1][2][23]. Industry Overview - In 2020, the biopharmaceutical market in China was valued at CNY 3,457 billion, increasing to CNY 4,100 billion in 2021, representing an 18.6% year-on-year growth. However, growth slowed to 2.68% in 2022, with a slight increase to CNY 4,210 billion [1][2]. - The industry is segmented into upstream (raw materials and medical devices), midstream (drug synthesis and production), and downstream (drug distribution). Biopharmaceuticals and chemical drugs have higher profit margins, with biopharmaceutical companies reporting gross margins of 80%-86% [2][4]. Xiamen Biopharmaceutical Industry - Xiamen is a key hub for biopharmaceutical industry development, recognized as a national strategic emerging industry cluster. The local government has implemented various supportive policies since 2016, focusing on innovation and industrialization [6][9]. - The industrial output value of Xiamen's biopharmaceutical sector reached CNY 1,045.87 billion in 2022, with a slight decline to CNY 847 billion in 2023, and is projected to stabilize around CNY 840 billion in 2024 [17][18]. Policy Environment - Xiamen's government has introduced multiple measures to support the biopharmaceutical industry, including financial incentives for R&D and commercialization, with significant rewards for new drug development and medical device innovation [9][26]. - The city aims to establish a CNY 100 billion venture capital fund and enhance the entire process from R&D to clinical application by 2025 [23][26]. Future Outlook - By 2025, Xiamen plans to significantly increase the number of registered biopharmaceutical companies, with projections indicating over 2,200 registered firms, marking a notable rise from previous years [18]. - The city aims to develop a CNY 700 billion biopharmaceutical industry chain, supported by specialized parks and a focus on various sub-sectors, including biopharmaceuticals and medical devices [23][26].

Group 1 - The core point of the article is that Huaxia Eye Hospital announced the resolutions passed during the first meeting of its fourth board of directors, including the election of the chairman and the appointment of the general manager [1] Group 2 - The company approved multiple resolutions, including the election of the chairman of the fourth board of directors and the election of members for the specialized committees [1] - The announcement reflects the company's governance structure and leadership changes, which may impact its strategic direction [1] - The appointment of the general manager is a significant step in the company's operational management [1]

Core Viewpoint - Huaxia Eye Hospital announced the approval of the proposals for the election of the fourth board of directors, including both non-independent and independent director candidates at the first extraordinary shareholders' meeting of 2026 [2] Group 1 - The company held its first extraordinary shareholders' meeting of 2026 on January 14 [2] - The proposals for the election of the fourth board of directors were approved during this meeting [2] - The proposals included nominations for both non-independent and independent director candidates [2]